- Home
- ADMA vs NUVL Comparison
ADMA vs NUVL Comparison
Compare ADMA & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADMA
- NUVL
- Stock Information
- Founded
- ADMA 2004
- NUVL 2017
- Country
- ADMA United States
- NUVL United States
- Employees
- ADMA N/A
- NUVL N/A
- Industry
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ADMA Health Care
- NUVL Health Care
- Exchange
- ADMA Nasdaq
- NUVL Nasdaq
- Market Cap
- ADMA 5.8B
- NUVL 5.6B
- IPO Year
- ADMA N/A
- NUVL 2021
- Fundamental
- Price
- ADMA $19.98
- NUVL $69.85
- Analyst Decision
- ADMA Strong Buy
- NUVL Strong Buy
- Analyst Count
- ADMA 4
- NUVL 8
- Target Price
- ADMA $24.25
- NUVL $115.50
- AVG Volume (30 Days)
- ADMA 4.5M
- NUVL 625.4K
- Earning Date
- ADMA 05-07-2025
- NUVL 05-08-2025
- Dividend Yield
- ADMA N/A
- NUVL N/A
- EPS Growth
- ADMA N/A
- NUVL N/A
- EPS
- ADMA 0.84
- NUVL N/A
- Revenue
- ADMA $459,381,000.00
- NUVL N/A
- Revenue This Year
- ADMA $18.45
- NUVL N/A
- Revenue Next Year
- ADMA $26.96
- NUVL N/A
- P/E Ratio
- ADMA $23.92
- NUVL N/A
- Revenue Growth
- ADMA 62.23
- NUVL N/A
- 52 Week Low
- ADMA $6.84
- NUVL $55.54
- 52 Week High
- ADMA $25.67
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- ADMA 43.06
- NUVL 46.22
- Support Level
- ADMA $18.75
- NUVL $63.56
- Resistance Level
- ADMA $23.98
- NUVL $78.97
- Average True Range (ATR)
- ADMA 1.38
- NUVL 3.46
- MACD
- ADMA -0.34
- NUVL -0.38
- Stochastic Oscillator
- ADMA 17.77
- NUVL 40.84
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.